PT  - JOURNAL ARTICLE
AU  - Dannenfelser, Rose-Marie
AU  - Surakitbanharn, Yosyong
AU  - Tabibi, S. Esmail
AU  - Yalkowsky, Samuel H.
TI  - Parenteral Formulation of Flavopiridol (NSC-649890)
DP  - 1996 Nov 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - 356--359
VI  - 50
IP  - 6
4099  - http://journal.pda.org/content/50/6/356.short
4100  - http://journal.pda.org/content/50/6/356.full
SO  - PDA J Pharm Sci Technol1996 Nov 01; 50
AB  - Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6′-chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither cosolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl ß-cyclodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen's phosphate buffer pH 7.4.